Compare MRKR & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRKR | CPHI |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.7M | 26.3M |
| IPO Year | 2010 | 2008 |
| Metric | MRKR | CPHI |
|---|---|---|
| Price | $1.52 | $0.55 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 132.2K | 8.2K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.61 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $4,144,268.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $936.27 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.81 | $0.50 |
| 52 Week High | $4.07 | $2.60 |
| Indicator | MRKR | CPHI |
|---|---|---|
| Relative Strength Index (RSI) | 51.74 | 41.32 |
| Support Level | $1.34 | $0.53 |
| Resistance Level | $1.55 | $0.66 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 44.91 | 24.12 |
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: MT-601; and MT-401-OTS.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.